Anzeige
Mehr »
Samstag, 21.06.2025 - Börsentäglich über 12.000 News
500 % Kursplus seit Januar. 462 g/t Goldgehalte. Mrd.-Investoren an Bord. Dieser finnische Junior wird heiß!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 883035 | ISIN: US8816242098 | Ticker-Symbol: TEV
Tradegate
20.06.25 | 21:43
14,600 Euro
-1,02 % -0,150
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD Chart 1 Jahr
5-Tage-Chart
TEVA PHARMACEUTICAL INDUSTRIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
14,70014,80013:04
14,60014,85020.06.

Aktuelle News zur TEVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiTeva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy10
DiTeva to collaborate with Fosun Pharma for TEV-562787
TEVA Aktie jetzt für 0€ handeln
MoTeva Pharmaceutical: Teva 2024 Healthy Future Report: Advancing Innovation and Collaboration342NORTHAMPTON, MA / ACCESS Newswire / June 16, 2025 / Improving access to medicines and healthcare requires a continued effort to develop new evidence-based solutions that address unmet needs. We engage...
► Artikel lesen
MoTeva, Fosun Pharma Partner to Develop Immuno-Oncology Therapy14
MoTeva, Shanghai Fosun Partner To Develop TEV-56278358PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Monday said that they have partnered to develop TEV-56278.Teva's TEV-56278...
► Artikel lesen
MoTeva and Fosun partner to develop TEV-56278 against cancers11
MoTeva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology122Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva...
► Artikel lesen
MoTeva Pharmaceutical Industries Ltd: Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology359Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established with...
► Artikel lesen
10.06.Teva Pharmaceutical: Teva Honored With Power of Partnership Award for Global Health Impact806NORTHAMPTON, MA / ACCESS Newswire / June 10, 2025 / Teva Pharmaceuticals has been recognized with the 2025 Power of Partnership Award by Americares, in collaboration with the Healthcare Distribution...
► Artikel lesen
10.06.Teva auf Goldman Sachs Konferenz: Strategische Neuausrichtung zur Biopharma42
06.06.Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?64
06.06.Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am39
06.06.Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space20
06.06.Teva Pharmaceutical: Teva 2024 Healthy Future Report: Health System Strengthening and Capacity Building738NORTHAMPTON, MA / ACCESS Newswire / June 6, 2025 / Teva Pharmaceutical:At Teva, we are all in for better health. Increasing access to quality medicines is fundamental to improving the health of patients...
► Artikel lesen
06.06.Goldman Sachs stuft Teva Pharm-Aktie mit "Kaufen" ein76
05.06.TEVA PHARMACEUTICAL INDUSTRIES LTD - 8-K, Current Report21
04.06.Teva bei Jefferies Healthcare: Strategisches Wachstum und Innovation38
04.06.Teva Pharmaceutical prices and manages debt40
03.06.Teva Pharmaceutical Industries Ltd: Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer439TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the pricing and early acceptance results of its previously announced...
► Artikel lesen
03.06.Teva Pharmaceutical Industries Ltd: Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement426TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced...
► Artikel lesen
Weiter >>
294 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,2